Thalys Medical Technology Group Corporation (SHA:603716)
15.95
-0.64 (-3.86%)
Nov 2, 2026, 3:00 PM CST
SHA:603716 Revenue
Thalys Medical Technology Group had revenue of 146.79M CNY in the quarter ending September 30, 2026, a decrease of -46.37%. This brings the company's total for the last twelve months to 709.31M, down -43.15% year-over-year. In the year 2025, Thalys Medical Technology Group had annual revenue of 1.08B, down -40.52%. That makes Thalys Medical Technology Group the 22,199th largest company in the world by revenue and 4,063rd in China.
Revenue (ttm)
709.31M
Revenue Growth
-43.15%
P/S Ratio
5.19
Revenue / Employee
678.77K
Employees
1,045
Market Cap
3.54B
Revenue by Segment
- Business 1.04B 96.1%
- Industry 41.64M 3.9%
Fiscal year ended Dec 31, 2025 See the full SHA:603716 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.08B | -733.73M | -40.52% |
| Dec 31, 2024 | 1.81B | -195.45M | -9.74% |
| Dec 31, 2023 | 2.01B | -302.50M | -13.10% |
| Dec 31, 2022 | 2.31B | -290.92M | -11.19% |
| Dec 31, 2021 | 2.60B | 474.08M | 22.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Runda Medical Technology | 6.52B |
| Maccura Biotechnology Co.Ltd | 2.18B |
| Medicalsystem Biotechnology | 1.68B |
| Beijing Strong Biotechnologies,Inc. | 1.37B |
| Shanghai Labway Clinical Laboratory | 1.28B |
| Amoy Diagnostics | 1.20B |
| Berry Genomics Co.,Ltd | 920.76M |
| SMO ClinPlus CO.,LTD. | 819.71M |